Teva is eyeing as many as 11 complex generics launches in the US this year, although it is realistic about achieving all of them and admits uncertainty over exactly which products it will introduce.
The Israeli firm has already delivered on one, a generic version of Merck & Co’s NuvaRing (etonogestrel/ethinyl estradiol) vaginal ring...




